 |
|
|
| |
Safety and tolerability of simeprevir (TMC435) in combination with peginterferon a-2a and ribavirin for treatment of HCV genotype 1 infection in treatment-naïve and -experienced patients (Phase IIb PILLAR and ASPIRE Trials)
|
| |
| |
Reported by Jules Levin
AASLD 2012 Boston Nov 10-14
Michael Fried,1 Fred Poordad,2 Stefan Zeuzem,3 Peter Ferenci,4 Oliver Lenz,5 Sivi Ouwerkerk-Mahadevan,6 Monika Peeters,5 Rekha Sinha,5 Maria Beumont-Mauviel5
1University of North Carolina at Chapel Hill, NC, USA; 2Cedars-Sinai Medical Center, Los Angeles, CA, USA; 3J.W. Goethe University Hospital, Frankfurt, Germany; 4Universitätsklinik für Innere Medizin III, Wien, Austria;
5Janssen Infectious Diseases BVBA, Beerse, Belgium; 6Janssen Research and Development, Beerse, Belgium
|
| |
|
|
|
|
|
